Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the pathogenesis of rheumatic diseases.Along with the clinical success of some of these targeted approaches, new information has been generated from their application concerning the pathophysiologic mechanisms underlying rheumatic diseases and, as a result, new targets have been identified.The ongoing dialogue between basic scientists, clinical investigators, metrologists and clinicians remains an essential component for the further development, refinement, integration and optimization of targeted therapies of the rheumatic diseases. The goal of this volume is to provide comprehensive, up to date information on all aspects of the rapidly evolving development of targeted therapies of the rheumatic diseases to foster further advances to improve therapy of patients with these conditions.
Targeted Therapies in Rheumatology established itself as an excellent reference for all those needing to know about the clinical implications of new drugs and developments for patients suffering from rheumatoid arthritis. This volume takes up the further developments that have occurred in several of the drug therapies covered in the first volume, as well as looking at the latest areas of promising research.
Review for the previous volume from Annals of Internal Medicine (140:2, 2004):
"This is a quality textbook that highlights the important advances that have enhanced, or are likely to enhance, the treatment of many serious chronic inflammatory and autoimmune diseases. Each of the authors was selected on the basis of their published contributions to an exciting literature"
Section I - Cells and cell surface receptors 1. T cells – overview – Update 2. Co-stimulation: a. CD80/86 – CD28 , CTLA-4 3. Regulatory T cells 4. B Cell Antigen Receptor Signalling and Autoimmunity 5. Plasma cells 6. Targeting B lymphocyte stimulator (BLyS) in immune-based rheumatic diseases: a therapeutic promise waiting to be fulfilled 7. Macrophages – overview – update 8. Dendritic cells 9. Toll-like receptors 10. Cadherins 11. Complement and pregnancy loss 12. Osteoclasts 13. Cell contact dependence of inflammatory events Section II - Cytokines, chemokines and other effector molecules 14. Update on TNFa 15. Targeting Interleukin-1 in Rheumatic Diseases – Update 16. Update on IL-6 17. Update on IL-15 18. Update on IL-18 19. Update on OPG/anti-RANKL 20. Interleukin-32 21. Interleukin-13 22. IL-17: a new target in arthritis 23. Interleukin 21 24. The Interferons 25. Update – Inflammatory, angiogenic and homeostatis chemokines and their receptors Section III - Transcription factors and signalling molecules 26. Update on NFkB 27. Update on Jak/STATs 28. Suppressor of cytokine signalling (SOCS) proteins as therapeutic targets in rheumatoid arthritis 29. The various pathways of cytokine signalling - Wnt Signalling 30. NFAT 31. Signalling in osteoclasts and osteoblasts Section IV - Inflammatory mediators 32. Inflammatory Mediators: Update on Cyclooxygenases and PG Synthases Section V - Matrix molecules 33. Update on Matrix metalloproteinases 34. The ADAM family of MMPs Section VI - Targeted therapies in human and experimental rheumatic diseases 35. Update on proinflammatory cytokine blockade in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis 36. Update on targeted therapy in psoriatic arthritis 37. Update on ankylosing spondylitis 38. Early Arthritis – Update 39. Juvenile arthritis – Update 40. Update – Systemic Lupus Erythmatosus 41. Vasculitis – update 42. Myositis – update 43. TNF-blockade in orphan rheumatic diseases 44. Overview of the safety of TNF inhibitors 45. Anti-CD20 46. CTLA-4Ig 47. Anti-IL6R 48. Anti-CD3 antibody – An History of successful immune interventions 49. Alefacept 50. Anti-VLA-4 51. Anti-IL-15 52. Clinical prospects of MAPK inhibitors 53. Clinical Prospects of NFkappaB Inhibitors to Advance Targeted Therapies in Rheumatology